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Summary
Disease modifying drugs for osteoarthritis (OA) that may halt or retard joint destruction and at the same time possibly improve symptoms are
being developed and tested at various stages in clinical trials. This has, for at least two reasons, focused attention on the need for
identification of patient groups at high risk for incident or progressive OA. First, well characterized such groups may be useful in clinical trials.
Second, assuming that disease modifying OA drugs become available in the future, primary target groups in need of such therapy have to
be identified. Risk factors for incident OA may differ from those for OA progression. Interactions between risk factors for OA is little
understood. Factors that have consistently been reported as associated with radiographic OA progression are obesity, generalized OA,
alignment and synovitis. Other factors such as bone scintigraphic lesions, joint injury nad biomarkers (such as type II collagen fragments,
COMP and HA) show promise. Further evaluation of these variables and their individual and combined influence will be useful to design a
risk profile for OA incidence and progression.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is a multifactorial disease involving
endogenous factors, such as age, sex, and genes, as well
as exogenous environmental factors such as load and
trauma. Convergence of these factors leads to the initiation
of the disease state. Whether the factors that lead to
disease initiation are the same that drive the disease from
its initiation to any of its various outcomes, such as osteo-
phyte formation, cartilage loss, and inflammation, has been
the topic of much discussion. Further, some data suggest
that the rate of progression of OA is variable; however,
publications on the natural history of OA remain sparse. A
search of the literature thus reveals very few good quality
studies that provide valid information on the rate of disease
progression. It is in this context that we ask whether we can
identify early on either those patients who will experience
rapid progression of disease or, equally important, those
patients who will not. Clearly, patients at risk for rapid
progression should be at the focus of our current and future
efforts to modify, i.e., slow or stop, disease progression in
OA. These patients also, in consequence, serve as a
population of interest for clinical trials of disease-modifying
drugs for OA.
Selection of patients for study
Researchers have focused on cohorts of patients be-
lieved to be at high risk for arthritis, such as obese women,
individuals with previously injured knees, and patients with
familial forms of OA or other subgroups of OA. It is thought
that selection of such high risk subjects may minimize the
number of study-subject-years required to demonstrate an
effect of treatment and may maximize the probability of
confirming or refuting one’s hypothesis.
However, is it appropriate to select subsets of subjects at
risk for rapidly progressing disease to maximize the likeli-
hood of detecting a treatment effect? Some would argue
that selection of specific subsets of patients is too labor
intensive, expensive, and time consuming. Also, the in-
creases in the mean rate of disease progression that can
be achieved through selection of such patients may not be
that great. On the other hand, use of selected subsets of
subjects may increase the likelihood of detecting a treat-
ment effect. Clearly, there are several ways of looking at the
criteria for selection of patients for OA studies.
Should we select OA subjects who deterio-
rate fast to maximize likelihood of detecting
treatment effect?
• NO
Finding these selected patients costs too much,
takes too long and doesn’t increase the mean
deterioration rate that much!
• YES
We’ll be more likely to detect effect of treatment!
What subjects should be selected for OA studies? A
study could examine a random sample of the entire popu-
lation, or the entire population of subjects with or without
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OA (Fig. 1). Such populations would be the preferred
source of study subjects for a natural history study, but not
for a clinical trial. Alternatively, a study might select subjects
who have OA symptoms, those who have only radiological
changes consistent with OA, or those subjects who have
the combination, ‘OA classic.’ Although subjects with both
symptoms and radiological change have been the focus of
much of our discussions and trials so far, there are other
options, and these are the subject of this paper.
Should the subjects selected for study of potential dis-
ease modification or prevention be those who are asymp-
tomatic and do not yet have radiographic changes but who,
for some reason, are at high risk of developing OA in the
future (corresponding to the bottom center circle in Fig. 1)?
Or should we select subgroups of subjects who have
symptoms of OA but no radiographic changes, or those
who have radiographic changes but no symptoms? All of
these may be valid study groups, but the problem with any
of these choices is that we do not know how many persons
fit into each of these subgroups or what is the ‘conversion
rate’ to ‘OA classic’ (‘Both’ in Fig. 1). In other words, how
much time is required for patients to cross over from one of
these subgroups to another, and what proportion will con-
vert in a given time period? Current large-scale investiga-
tions such as the Osteoarthritis Initiative are underway to
generate such information1.
What are the consequences of the risk factors
for osteoarthritis?
At this point, we do not fully understand the conse-
quences of the various risk factors for OA. Are we inter-
ested in the risk factors that predispose patients to new
disease, or those that are associated with progression of
existing disease? Or are we interested in the risk factors
that characterize the subgroup of patients who will have
rapidly progressing disease? Answers to these questions
are not straightforward. Longitudinal studies of OA are
complicated by the fact that, generally speaking, during the
period of a usually slow progression from a normal joint
to end stage OA, patients age significantly. Thus, age-
associated changes in joint structure and symptoms are a
factor to consider in longitudinal studies in OA.
In a study of OA incidence, patients are followed along a
continuum progressing from a more or less normal state to
a disease state. At some point, the patient crosses a
borderline between what is recognized as absence of overt
OA to presence of overt OA (Fig. 2). It is important to note
that the distinction between incident cases of OA and
progression of prevalent cases depends on where along
the continuum patients are considered to have overt OA. If,
for some reason, we become better at diagnosing OA, and
overt OA is detected earlier, the definitions will change, and
then these criteria will change, perhaps even during the
course of a long-term natural history study. Similarly, if OA
is diagnosed later, cases formerly considered to be ‘pro-
gression cases’ will now be considered ‘incident cases.’
Thus, the definitions used to describe incident or prevalent
cases of OA will critically depend on the criteria we use to
define OA. These considerations are important in develop-
ing a high risk patient profile and in determining exactly
what is being examined.
Understanding interactions between risk factors
Development of a high risk patient profile is further
complicated because we do not yet fully understand the
interactions between the risk factors for OA, such as age,
genetics, obesity, and joint injury. For example, if we
assume a ‘background’ rate of progression (or incidence) of
OA in the population, what is the effect of adding a specific
genetic risk or a joint injury risk? Does the proportion of
individuals entering the ‘OA pathway’ (diagonal line in Fig.
2) increase, and the rate of disease progression remain the
same in the presence of the added risk factors? Or does
the addition of a specific risk factor change the rate of
disease progression (dashed, diagonal line with increased
slope in Fig. 2)? Do certain risk factors for OA become
active only in certain environments, in the presence of other
factors, in a ‘permissive environment’?
Fig. 1. Which subjects to select for osteoarthritis (OA) studies:
Random selection from population or non-random selection from
putative high-risk groups? The ‘conversion rate’ from one group to
another is not well understood.
Fig. 2. Graphic presentation of the ‘background’ progression (blue
line) of osteoarthritis (OA) from ‘no OA’ to ‘overt OA’ (shaded zone)
over time. A putative effect of a joint insult may be an increase in
the rate of disease progression (dashed line with steeper slope).
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In summary, we do not yet fully know how risk factors
interact to affect the incidence or rate of disease progres-
sion in OA. Understanding these factors and the relation-
ships between them are critical to designing studies
that will ask the right questions and provide the answers
necessary to develop effective means of treating and
managing OA.
Factors associated with joint space loss in
longitudinal knee osteoarthritis studies
Longitudinal studies by Dougados, Dieppe, and others
have evaluated factors possibly associated with knee OA,
including obesity, the number of joints affected, pain sever-
ity, and nonsteroidal anti-inflammatory drug (NSAID) use
(Table I)2–5. The findings from these studies indicate that
obesity and the number of joints affected are associated
with joint space loss6. Joint injury represents another
important risk factor for OA7–9. Periarticular bone uptake on
bone scan may identify knees and hands prone to radio-
graphic progression10. While the above factors have been
shown in one study or consistently by at least two to identify
knees prone to progression, evaluations of the relationship
between pain severity and disease progression have pro-
duced variable results2,3,5. Other factors reported to be
linked to a high risk of X-ray progression in at least one
study include low vitamin D levels11,12, low vitamin C
intake13, and low (not high) bone density14.
One of the most potent set of factors yet identified is limb
malalignment, both static and dynamic. Static alignment is
limb alignment when standing. Dynamic alignment is align-
ment during motion and is usually assessed in the lower
limbs during walking. In normal limbs, static alignment is
collinear (or neutral), and dynamic alignment shows an
excess of varus torque which excessively loads the medial
compartment. Sharma and colleagues, in an 18-month
follow-up study of persons with symptomatic knee OA,
reported that varus static alignment increased markedly the
risk of medial joint space progression (adjusted odds ratio
[OR]=4.09), whereas valgus static alignment increased
the risk of lateral progression (OR=4.89)15. While this is the
most potent risk factor for structural progression yet de-
scribed, Miyazaki and coworkers suggest that dynamic
malalignment may be even stronger16. In a 6-year
follow-up study, varus torque in a limb identified almost all
of the knees destined to show medial progression (lateral
progression was not examined). Specifically, 80% of pro-
gressors had a high varus torque (>=5 weight X height),
and when both static and dynamic alignment were exam-
ined together, dynamic alignment was more predictive of
progression.
Synovitis is associated with worsening of patello-femoral
chondropathy, and effusion with higher Kellgren-Lawrence
grades.
What biomarkers are associated with
radiographic progression of OA
A rich literature exists on biomarkers of OA. One of the
suggested roles of the biomarkers is to predict disease
progression17,18. Biomarkers that have been suggested to
be associated with radiographic progression of OA include
serum C-reactive protein (CRP), serum hyaluronic acid
(HA), serum cartilage oligomeric matrix protein (COMP),
and type II collagen fragments19–24. Interestingly, many of
these markers are believed to be associated in some way
with an inflammatory process, perhaps in the form of
synovitis. Other biochemical markers are also being
assessed, some of which will likely be added to this list.
Which factors contribute to a high risk profile?
The elements making up a high risk profile would un-
doubtedly include demographics, signs and symptoms,
structural changes, and almost certainly, genetic back-
ground. With further work, biomarkers may also contribute
to the risk profile. Evaluation of these elements, as well as
combinations of these factors, will be important in design-
ing a profile that will describe patients at high risk for
developing OA.
Discussion
Male Voice: Bone mineral density is on your list of
possible but not well studied risks. And yet, I heard yester-
day that subchondral sclerosis is actually associated with
OA.
Dr Hochberg: In the longitudinal Framingham OA study,
in people who didn’t have knee OA at the time of first X-ray,
higher levels of bone mineral density, measured close to
the time of the first X-ray, were associated with an in-
creased risk of developing incident knee OA. In contrast, in
those who did have knee OA at the time of first X-ray, those
who were in the lowest quartile of femoral neck bone
mineral density were more likely to have progressive radio-
graphic changes, as defined by loss of minimum joint
space. It may be that higher levels of bone mineral density
is a risk marker, as opposed to risk factor, for developing
radiographic OA at the knee and at the hip. Data from the
Framingham study suggest that in people who have radio-
graphic OA, as defined by an increase in osteophytes, low
bone mineral density is a risk marker for progression of
cartilage loss, as measured by a decrease in interbone
distance.
Dr Lohmander: And you pointed out again that much of
this discussion depends on how we define progression of
OA. Progression of what? Loss of joint space? Or increase
of osteophytes? Or a combination thereof?
Male Voice: One issue to consider when selecting a high
risk profile is whether post-traumatic OA, in the knee in
particular, and other types of OA are the same disease.
Would they have the same natural history, or accelerated
natural history, and would they respond to treatment in the
same fashion? This issue should be considered when
selecting a profile for the high risk patient.
Table I
Factors that affect radiographic progression of osteoarthritis




Not well studied, but promising
· Alignment
· Injury
· Late phase bone scintigraphic lesions
· Low vitamin D level
· Low bone mineral density
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Dr Lohmander: That comment of course goes to the
heart of the matter: are these subgroups truly represen-
tative of the whole population of garden variety OA? There
is no evidence to suggest that knee OA associated with, for
example, obesity or joint injury is different from ‘garden
variety OA.’ They may all be different, yes, but is any one of
them more different than the others? There is currently no
evidence to suggest either way.
Male Voice: We didn’t discuss generalized OA much in
the meeting, although it was listed as a risk factor for
progression. Does generalized OA really exist?
Dr Lohmander: I must confess that I think we’re quite
primitive in our way of looking at the disease. We are using
a lot of traditional definitions, which I believe will not survive
the next few years. Some of the genetic work is hinting that
OA is a lot more complex than we used to think, with some
genetic associations pointing towards ‘osteophytic OA,’ and
others pointing towards ‘joint space loss OA.’ It also ap-
pears that some genetic associations are linked to specific
sites, whereas others may be of a more general nature.
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